FDA says Ezra's website misbrands compounded semaglutide and tirzepatide by labeling them as Ezra-made when they are not.
What happened
FDA reviewed Ezra's website in May 2026 and found compounded semaglutide and tirzepatide products offered for sale. FDA said the pictured labels identify "Ezra" in a way that suggests Ezra is the compounder when it is not, making the products misbranded.
What FDA found
The website labels for compounded semaglutide and tirzepatide show "Ezra," suggesting Ezra made the drugs when it did not, so the labeling is false or misleading.
FD&C Act §502(a) [21 U.S.C. §352(a)]; 21 C.F.R. §201.1(h)(2)The advertising or promotion of the compounded semaglutide and tirzepatide products is false or misleading because of the same Ezra labeling.
FD&C Act §502(bb) [21 U.S.C. §352(bb)]The misbranded compounded drugs were introduced or delivered for introduction into interstate commerce.
FD&C Act §301(a) [21 U.S.C. §331(a)]
What FDA wants
FDA tells Ezra to respond in writing within 15 business days to CDER's Office of Compounding Quality and Compliance, identify the entities that make the compounded drugs, provide sample labeling, and correct or remove false or misleading website claims.
Who should pay attention
- telehealth companies selling compounded semaglutide or tirzepatide
- marketers that use their own brand on compounded drug labels
- compounding pharmacies and contract manufacturers supplying these products
This is a summary. Read the original letter on fda.gov.